Two years after the FDA guidance on Control of Nitrosamines Impurities in Human Drugs and nearly a year after the publication of USP’s General Chapter <1469> Nitrosamine Impurities, where are we now and what have we learned? That was a question posed recently at the Association of Accessible Medicine’s GRx+Biosims 2022 conference. The session devoted […]
Many in the pharmaceutical industry that do business or have products that are distributed in the state of California are aware that they like to do things a little differently there. Some of our clients have reached out to ask about a law that is hitting their radar. It is known as the California Pharmaceutical […]
The first day of the Food and Drug Law Institute’s Annual Conference started with an excellent keynote address from FDA Commissioner Dr. Robert Califf, who underscored the importance of the FDA engaging with industry to evaluate the promise (as well as risks) of new technology and medicinal products. Part of that dialogue happens at the individual […]
